| Literature DB >> 31776701 |
Nduka C Okwose1, Leah Avery2, Nicola O'Brien3, Sophie Cassidy1, Sarah J Charman1, Kristian Bailey4, Lazar Velicki5,6, Iacopo Olivotto7, Paul Brennan4,8, Guy A MacGowan1,4,8, Djordje G Jakovljevic9,10,11.
Abstract
PURPOSE: Less than 10% of heart failure patients in the UK participate in cardiac rehabilitation programmes. The present pilot study evaluated feasibility, acceptability and physiological effects of a novel, personalised, home-based physical activity intervention in chronic heart failure.Entities:
Keywords: Behavioural change; Chronic heart failure; Home-based intervention; Physical activity
Year: 2019 PMID: 31776701 PMCID: PMC6881484 DOI: 10.1186/s40798-019-0216-x
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Mean and SD (±) of patients’ demographic and clinical characteristics
| Parameter | |
| Age (years) | 68 ± 7 |
| Men/women | 18/2 |
| Weight (kg) | 84 ± 15 |
| Height (cm) | 1.72 ± 0.1 |
| Aetiology of HF (IHD/DCM) | 10/10 |
| LVEF (%) | 31 ± 8 |
| Medication | |
| ACE inhibitors | 15 |
| β-blockers | 20 |
| ARBs | 5 |
| Diuretics | 13 |
| Anti-arrhythmic | 3 |
| NSAIDs/pain killers | 6 |
| Warfarin | 5 |
| ICD/pacemakers | 13 |
| Comorbidities | |
| COPD | 1 |
| Type 2 diabetes | 5 |
| Obesity | 6 |
| Hypertension | 20 |
| Depression | 2 |
| Arthritis | 1 |
ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, LVEF left ventricular ejection fraction, NSAID non-steroid anti-inflammatory drugs, IHD, ischaemic heart disease, DCM dilated cardiomyopathy, COPD chronic obstructive pulmonary disease, ICD implantable cardioverter defibrillator
Fig. 1Flow diagram showing patient screening and recruitment into Active-at-home HF intervention
Fig. 2Mean (+ SD) number of steps achieved at baseline and at the end of weeks 3 and 12 of physical activity intervention
Cardio-metabolic changes (mean ± SD) following 12 weeks of Active-at-Home-HF intervention
| Pre-intervention | Post-intervention | % change | ||
|---|---|---|---|---|
| Measurements at rest | ||||
| Oxygen consumption (ml/kg/min) | 3.8 ± 1.0 | 4.1 ± 0.8 | 0.36 | 7.9 |
| Respiratory exchange ratio | 0.85 ± 0.1 | 0.85 ± 0.1 | 0.92 | 0 |
| Heart rate (beats/min) | 67 ± 7 | 70 ± 7 | 0.24 | 4.5 |
| Stroke volume index (ml/beat) | 48 ± 9 | 49 ± 8 | 0.75 | 2.0 |
| Cardiac output (l/min) | 6.1 ± 1 | 6.6 ± 1 | 0.14 | 8.2 |
| Systolic blood pressure (mmHg) | 118 ± 18 | 124 ± 18 | 0.41 | 4.0 |
| Diastolic blood pressure (mmHg) | 74 ± 8 | 76 ± 12 | 0.74 | 2.6 |
| Mean arterial pressure (mmHg) | 90 ± 9 | 92 ± 13 | 0.66 | 2.2 |
| Measurements at peak exercise | ||||
| Oxygen consumption (ml/kg/min) | 16.8 ± 3.8 | 17.6 ± 4.2 | 0.54 | 4.8 |
| Respiratory exchange ratio | 1.05 ± 0.1 | 1.07 ± 0.1 | 0.62 | 1.9 |
| Heart rate (beats/min) | 106 ± 19 | 107 ± 16 | 0.92 | 1.0 |
| Stroke volume (ml/beat) | 127 ± 34 | 151 ± 34 | 0.05 | 18.9 |
| Stroke volume index (ml/beat/m2) | 64 ± 14 | 75 ± 17 | 0.04 | 17.2 |
| Cardiac output (l/min) | 13.4 ± 4 | 15.3 ± 4.9 | 0.19 | 14.2 |
| Cardiac index (l/min/m2) | 6.8 ± 1.5 | 7.6 ± 2.0 | 0.19 | 11.7 |
| Systolic blood pressure (mmHg) | 155 ± 30 | 150 ± 30 | 0.62 | 3.2 |
| Diastolic blood pressure (mmHg) | 80 ± 8 | 79 ± 8 | 0.72 | 1.3 |
| Mean arterial pressure (mmHg) | 103 ± 13 | 102 ± 13 | 0.87 | 1.0 |
| Peak exercise workload (watts) | 82 ± 10 | 91 ± 19 | 0.21 | 11 |
| Exercise workload at anaerobic threshold (watts) | 49 ± 16 | 59 ± 14 | 0.01 | 20 |
| Oxygen consumption at anaerobic threshold (ml/kg/min) | 11.5 ± 2.9 | 12.8 ± 2.2 | 0.39 | 11.3 |
| Rate of perceived exertion | 16 ± 2.4 | 17 ± 2.3 | 0.22 | 6.3 |
Blood biomarkers and quality of life (mean ± SD) following 12 weeks of Active-at-Home-HF
| Pre-intervention | Post-intervention | % change | ||
|---|---|---|---|---|
| Cholesterol (mmol/l) | 4.0 ± 0.9 | 3.9 ± 0.9 | 0.59 | 2.5 |
| Triglyceride (mmol/l) | 1.5 ± 0.7 | 1.8 ± 0.9 | 0.45 | 20 |
| HDL (mmol/l) | 1.2 ± 0.3 | 1.1 ± 0.3 | 0.67 | 8.3 |
| LDL (mmol/l) | 2.1 ± 0.7 | 1.9 ± 0.7 | 0.46 | 9.5 |
| HbA1c (mmol/mol) | 49.2 ± 17.3 | 47.5 ± 12 | 0.77 | 3.5 |
| FBG (mmol/l) | 6.2 ± 2.9 | 7.0 ± 3.8 | 0.56 | 12.9 |
| NT proBNP (pg/ml) | 823 ± 1085 | 876 ± 1114 | 0.89 | 6.4 |
| Renal function eGFR | 65.4 ± 18.6 | 61.4 ± 17.4 | 0.61 | 6.1 |
| QoL | 26 ± 18 | 22 ± 23 | 0.50 | 15.4 |
HDL high-density lipoprotein, LDL low-density lipoprotein, HBA1c glycated haemoglobin, FBG fasting blood glucose, NT proBNP N-terminal brain natriuretic peptide, QoL quality of life, eGFR glomerular filtration rate
Fig. 3Relationship between number of steps and peak oxygen consumption pre- and post-intervention